Barclays
FLNA

Barclays’s Filana Therapeutics FLNA Stock Holding History

Barclays’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$347 Sell
292
-42,087
-99% -$60K ﹤0.01% 5052
2026
Q1 		$71.6K Sell
42,379
-6,083
-13% -$12.5K ﹤0.01% 4173
2025
Q4 		$96K Buy
48,462
+48,371
+53,155% +$155K ﹤0.01% 4592
2025
Q3 		$265 Sell
91
-2,643
-97% -$6.08K ﹤0.01% 5234
2025
Q2 		$4.95K Sell
2,734
-41,396
-94% -$73.7K ﹤0.01% 4974
2025
Q1 		$66.2K Sell
44,130
-49,449
-53% -$125K ﹤0.01% 4535
2024
Q4 		$221K Buy
93,579
+18,832
+25% +$331K ﹤0.01% 4260
2024
Q3 		$2.2M Buy
74,747
+53,487
+252% +$1.23M ﹤0.01% 2780
2024
Q2 		$263K Sell
21,260
-30,098
-59% -$634K ﹤0.01% 3422
2024
Q1 		$1.04M Sell
51,358
-54,232
-51% -$1.25M ﹤0.01% 3090
2023
Q4 		$2.38M Buy
105,590
+78,888
+295% +$1.67M ﹤0.01% 2775
2023
Q3 		$444K Buy
26,702
+6,711
+34% +$133K ﹤0.01% 2867
2023
Q2 		$490K Sell
19,991
-12,510
-38% -$301K ﹤0.01% 2764
2023
Q1 		$784K Sell
32,501
-11,155
-26% -$309K ﹤0.01% 2920
2022
Q4 		$1.29M Buy
43,656
+22,114
+103% +$795K ﹤0.01% 2593
2022
Q3 		$901K Buy
21,542
+902
+4% +$24.4K ﹤0.01% 2318
2022
Q2 		$581K Sell
20,640
-3,621
-15% -$91.4K ﹤0.01% 2761
2022
Q1 		$901K Sell
24,261
-86,747
-78% -$3.68M ﹤0.01% 2491
2021
Q4 		$4.85M Buy
111,008
+54,207
+95% +$2.84M ﹤0.01% 1730
2021
Q3 		$3.52M Buy
56,801
+51,960
+1,073% +$4.34M ﹤0.01% 1874
2021
Q2 		$414K Sell
4,841
-22,491
-82% -$1.2M ﹤0.01% 3182
2021
Q1 		$1.23M Buy
27,332
+16,718
+158% +$658K ﹤0.01% 2649
2020
Q4 		$72K Sell
10,614
-66
-0.6% -$589 ﹤0.01% 4263
2020
Q3 		$122K Sell
10,680
-18,602
-64% -$83.9K ﹤0.01% 4143
2020
Q2 		$91K Buy
+29,282
New +$133K ﹤0.01% 4583
2013
Q4 		– Sell
-135
Closed -$2K – 7658
2013
Q3 		$2K Sell
135
-7,610
-98% -$133K ﹤0.01% 7205
2013
Q2 		$120K Buy
+7,745
New +$164K ﹤0.01% 5637

Other funds holding FLNA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Barclays's FLNA Position: Q2 2026 in Review

Barclays reduced its Filana Therapeutics (FLNA) stake by 99% in Q2 2026, selling an estimated $60K and leaving 292 shares worth $347. The position accounts for ﹤0.01% of the portfolio, ranked #5052.

Barclays first reported a position in FLNA in Q2 2013 and has held it in 27 quarters since. The position peaked at $4.85M in Q4 2021. 84 funds tracked by Wall St. Rank hold FLNA as of Q2 2026.

  • Barclays held 292 shares of Filana Therapeutics worth $347 as of Q2 2026.
  • Barclays sold 42,087 Filana Therapeutics shares in Q2 2026, an estimated $60K.
  • Filana Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5052 holding.
  • Barclays first reported a position in Filana Therapeutics in Q2 2013 and has held it in 27 quarters since.
  • Barclays's Filana Therapeutics position peaked at $4.85M in Q4 2021.
  • 84 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.